secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001437749-24-016364
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path
-----------------------------------------------------------------

- Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.
- Cash $12.0M as of March 31, 2024, down from $23.4M at December 31, 2023.
- FDA aligned on registrational Phase 3 program for brilaroxazine in schizophrenia; RECOVER-2 trial start expected Q2 2024.
- Topline data from 1-year OLE trial expected Q4 2024; potential NDA submission targeted for Q4 2025.
- Company initiated Phase 3 RECOVER-1 data presentations at SIRS and ASCPT meetings in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/0001437749-24-016364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924016364/rvph20240510_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer